Tiziana Life Sciences Share Price - TLSA

5.80
0.07 (1.22%)
Upgrade to Real-Time
Afterhours (Closed)
5.73
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Tiziana Life Sciences PLC TLSA NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.58 11.26% 5.73 5.30 5.90 5.75 5.15 00:00:02
Bid Price Ask Price Spread Spread % News
4.60 5.80 1.20 20.69% 1 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,700 366,391  5.62  2,059,219 370,836 1.54 - 7.70
Last Trade Time Type Quantity Stock Price Currency
19:47:06 16  5.80 USD

Tiziana Life Sciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 184.24M 32.15M 32.15M  -  - -0.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Tiziana Life Sciences

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

TLSA Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Tiziana Life Sciences PLC is involved in the business of developing novel therapeutics for cancer with a focus on late-stage growth and complementary diagnostic tools, with the capability of predicting disease aggressiveness and prognosis in breast cancer patients. The group also has interests, beyond pure oncology, in the discovery and development of monoclonal antibody-based biologics used to benefit patients with inflammatory and auto-immune disorders. The company has a single reporting segment, The Research, and Development of Biotechnological and Pharmaceutical Products. Its lead compound, milciclib (TZLS-201), is a molecule which blocks the action of specific enzymes involved in cell division as well as a number of other protein kinases.


Your Recent History
NASDAQ
TLSA
Tiziana Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.